迈克生物：9月29日召开董事会会议

Group 1 - The core point of the news is that Maike Bio (SZ 300463) held its sixth board meeting on September 29, 2025, to discuss the revision of the board meeting rules [1] - For the first half of 2025, Maike Bio's revenue composition was entirely from in vitro diagnostics, accounting for 100% [2] - As of the report date, Maike Bio's market capitalization was 7 billion yuan [2] Group 2 - The competition between Nongfu Spring and Yibao has intensified, with Nongfu Spring's green bottle launch leading to a significant market share decline for Yibao, dropping nearly 5 percentage points [2]